Literature DB >> 32267957

Accelerated Corneal Cross-linking as an Adjunct Therapy in the Management of Presumed Bacterial Keratitis: A Cohort Study.

Boris Knyazer, Yonit Krakauer, Muhammad Abu Tailakh, Asaf Achiron, Idan Hecht, Tova Lifshitz, Emilio A Torres-Netto, Nikki L Hafezi, Farhad Hafezi.   

Abstract

PURPOSE: To compare the outcomes of accelerated photoactivated chromophore for keratitis corneal cross-linking (PACK-CXL) as an adjunct treatment for bacterial keratitis (PACK-CXL plus standard antibiotic therapy) for patients receiving only standard antibiotic therapy.
METHODS: Retrospective cohort study of outcomes of patients with moderate infectious presumed bacterial keratitis (ulcer diameter 2 to 7 mm and stromal depth < 300 µm) were compared before and after initiation of a new treatment protocol of PACK-CXL in addition to standard antibiotic treatment.
RESULTS: A total of 70 eyes of 70 patients were included: 39 eyes in the PACK-CXL plus antibiotic (PACK-ABX) group and 31 eyes in the antibiotic only (ABX) control group. The PACK-ABX group showed shorter times to complete reepithelialization (9.3 ± 6.0 vs 16.0 ± 12.7 days, P = .01) and did not require tectonic emergency keratoplasty (0% versus 19.4%, P = .006). The PACK-ABX group also showed a higher percentage of eyes with complete reepithelialization in 6 days or less (46.2% vs 6.5%, P < .001) and a trend for shorter hospitalizations (6.3 ± 5.0 vs 8.5 ± 4.5 days, P = .06). A multivariate analysis controlling for age showed that PACK-ABX treatment remained significantly associated with early ulcer reepithelialization (odds ratio = 0.09, 95% confidence interval = 0.02 to 0.48, P = .005).
CONCLUSIONS: This study validates previous findings regarding the use of accelerated PACK-CXL in the treatment of bacterial keratitis. Adding PACK-CXL improved clinical outcomes (reducing healing time) when compared to antibiotics alone. [J Refract Surg. 2020;36(4):258-264.]. Copyright 2020, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32267957     DOI: 10.3928/1081597X-20200226-02

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  3 in total

1.  PACK-CXL vs. antimicrobial therapy for bacterial, fungal, and mixed infectious keratitis: a prospective randomized phase 3 trial.

Authors:  Farhad Hafezi; Mohammed Hosny; Rohit Shetty; Boris Knyazer; Shihao Chen; Qinmei Wang; Hassan Hashemi; Emilio A Torres-Netto
Journal:  Eye Vis (Lond)       Date:  2022-01-07

2.  The bactericidal effect of two photoactivated chromophore for keratitis-corneal crosslinking protocols (standard vs. accelerated) on bacterial isolates associated with infectious keratitis in companion animals.

Authors:  Anja Suter; Sarah Schmitt; Ella Hübschke; Malwina Kowalska; Sonja Hartnack; Simon Pot
Journal:  BMC Vet Res       Date:  2022-08-17       Impact factor: 2.792

Review 3.  Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases.

Authors:  Duoduo Wu; Dawn Ka-Ann Lim; Blanche Xiao Hong Lim; Nathan Wong; Farhad Hafezi; Ray Manotosh; Chris Hong Long Lim
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.